Neuroendocrine Prostate Cancer Market Projected for 25% Growth by 2036

While the market size for neuroendocrine prostate cancer stood at USD 5 million across the 7MM in 2025, the landscape is shifting rapidly. With approximately 24,500 incident cases recorded that same year, pharmaceutical developers are prioritizing targeted and precision treatments to replace or supplement traditional platinum-based chemotherapy. Current clinical efforts are heavily focused on innovative modalities, including DLL3-targeted therapies, antibody-drug conjugates, and bispecific T-cell engagers.

Key pipeline candidates such as Amgen’s Tarlatamab and Phanes Therapeutics’ Peluntamig are under intense evaluation to improve patient outcomes. According to Aparna Thakur, a project manager at DelveInsight, regulatory approval for agents like Tarlatamab could trigger rapid market uptake, given the current dearth of effective alternatives. As molecular profiling technologies—ranging from genomic testing to circulating tumor DNA analysis—become more sophisticated, clinicians are better positioned to identify aggressive neuroendocrine features, further driving demand for these emerging, biomarker-driven treatment regimens.